A controlled clinical trial suggests a fast-acting psychedelic approach may reduce depressive symptoms, but researchers stress careful interpretation and the need for larger long-term studies.
Study: A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial. Image Credit: BLACKDAY / Shutterstock
In a recent study published in the journal Nature Medicine, researchers evaluated the safety and efficacy of a short-acting psychedelic, dimethyltryptamine (DMT), in adults with major depressive disorder (MDD).
MDD is a leading global cause of disability, impacting quality of life and creating a significant public health burden. Many patients experience insufficient responses or unacceptable side effects with commonly used first-line treatments such…